Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Phase III data reveal effects of add-on dapagliflozin in poorly controlled diabetes

July 14, 2010

Merck & Co. characterizes new histamine H3 receptor ligands

July 14, 2010

ARYx claims novel PPAR-alpha agonists

July 14, 2010

Ostarine increases lean body mass and leg strength in postmenopausal women

July 14, 2010

JDRF awards Biodel grants for its VIAject diabetes therapy

July 13, 2010

FDA accepts Protalix's NDA for taliglucerase alfa

July 13, 2010

Viamet describes new cytochrome P450-C17 inhibitors

July 13, 2010

Exelixis presents preclinical data on agents investigated for diabetes

July 13, 2010

BHT-3021 shows promise in phase I/II trial in type 1 diabetes

July 13, 2010

Merck & Co. claims new glucagon receptor antagonists

July 13, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 8, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
GDE4 blockade promotes remyelination, study finds
BioWorld Science
Myelin is crucial for the correct functioning of nerve signaling and its loss is a feature of neurological disorders. The cells responsible for myelination in the...